PMID- 22173662
OWN - NLM
STAT- MEDLINE
DCOM- 20120504
LR  - 20151119
IS  - 1556-1380 (Electronic)
IS  - 1556-0864 (Linking)
VI  - 7
IP  - 1
DP  - 2012 Jan
TI  - Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly 
      patients with advanced or recurrent nonsquamous non-small cell lung cancer: 
      safety of avastin in lung trial (MO19390).
PG  - 203-11
LID - 10.1097/JTO.0b013e3182370e02 [doi]
AB  - INTRODUCTION: Safety of Avastin in Lung (MO19390) was an international, 
      open-label, single-arm study, which assessed the safety and efficacy of 
      first-line bevacizumab (Avastin(R)) in combination with standard chemotherapy in 
      patients (n = 2212) with advanced or recurrent non-small cell lung cancer 
      (NSCLC). A preplanned subgroup analysis was performed to examine these outcomes 
      in elderly patients older than 65 years. METHODS: Eligible patients with 
      nonsquamous NSCLC received up to six cycles of bevacizumab (7.5 or 15 mg/kg) plus 
      any standard of care chemotherapy. Patients who did not experience disease 
      progression after induction therapy continued bevacizumab therapy until disease 
      progression or unacceptable toxicity. The primary end point was safety; secondary 
      end points included time to disease progression (TTP) and overall survival (OS). 
      RESULTS: Data were evaluated for 623 patients older than 65 years (mean age 
      70.6). The majority were Whites (86.2%) with stage IV disease (79.7%) and had 
      adenocarcinoma (83.5%). The incidence of adverse events (AEs) of special interest 
      was similar for elderly and younger patients (any grade bleeding 38.2% versus 
      38.3%; any grade hypertension 33.1% versus 30.6%; any grade proteinuria 33.4% 
      versus 29.3%). Most AEs were grade less than or equal to 2. Serious AEs were 
      reported in 45.3 and 34.7% of elderly and younger patients, respectively. Median 
      OS was similar in elderly and younger patients (14.6 months in both age groups), 
      as were TTP (8.2 versus 7.6 months), response rate (49.3% versus 52.4%), and 
      disease control rate (89.3% versus 88.4%). Similar results were seen in a post 
      hoc comparison of the older than 70 years and 70 years or younger subgroups: TTP 
      was 8.6 months versus 7.7 months, respectively; OS was 14.6 months in both 
      subgroups; response rate was 49% and 52%, respectively; incidence of AEs of 
      special interest was comparable. CONCLUSION: Patients older than 65 years with 
      nonsquamous NSCLC derive a similar clinical benefit from first-line 
      bevacizumab-based therapy as their younger counterparts and do not experience 
      increased toxicity.
FAU - Laskin, Janessa
AU  - Laskin J
AD  - Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, 
      British Columbia, Canada. jlaskin@bccancer.bc.ca
FAU - Crino, Lucio
AU  - Crino L
FAU - Felip, Enriqueta
AU  - Felip E
FAU - Franke, Fabio
AU  - Franke F
FAU - Gorbunova, Vera
AU  - Gorbunova V
FAU - Groen, Harry
AU  - Groen H
FAU - Jiang, Guo-Liang
AU  - Jiang GL
FAU - Reck, Martin
AU  - Reck M
FAU - Schneider, Claus-Peter
AU  - Schneider CP
LA  - eng
PT  - Clinical Trial, Phase IV
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - J Thorac Oncol
JT  - Journal of thoracic oncology : official publication of the International 
      Association for the Study of Lung Cancer
JID - 101274235
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - BG3F62OND5 (Carboplatin)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/pathology
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal, Humanized/*adverse effects/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use
MH  - Bevacizumab
MH  - Carboplatin/administration & dosage/adverse effects
MH  - Carcinoma, Large Cell/*drug therapy/pathology
MH  - Cisplatin/administration & dosage/adverse effects
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Epistaxis/chemically induced
MH  - Hemorrhage/*chemically induced
MH  - Humans
MH  - Hypertension/chemically induced
MH  - Lung Diseases/chemically induced
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*drug therapy
MH  - Neutropenia/chemically induced
MH  - Proteinuria/chemically induced
MH  - Survival Analysis
MH  - Wound Healing/drug effects
MH  - Young Adult
EDAT- 2011/12/17 06:00
MHDA- 2012/05/05 06:00
CRDT- 2011/12/17 06:00
PHST- 2011/12/17 06:00 [entrez]
PHST- 2011/12/17 06:00 [pubmed]
PHST- 2012/05/05 06:00 [medline]
AID - S1556-0864(15)31779-2 [pii]
AID - 10.1097/JTO.0b013e3182370e02 [doi]
PST - ppublish
SO  - J Thorac Oncol. 2012 Jan;7(1):203-11. doi: 10.1097/JTO.0b013e3182370e02.